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Background: The strong association between family history and prostate cancer (PCa) suggests a significant
genetic contribution, yet specific highly penetrant PCa susceptibility genes have not been identified. Certain
single-nucleotide-polymorphisms have been found to correlate with PCa risk; however uncertainty remains regarding
their clinical utility and how to best incorporate this information into clinical decision-making. Genetic testing is available
directly to consumers and both patients and healthcare providers are becoming more aware of this technology.
Purchasing online allows patients to bypass their healthcare provider yet patients may have difficulty interpreting test
results and providers may be called upon to interpret results. Determining optimal ways to educate both patients and
providers, and strategies for appropriately incorporating this information into clinical decision-making are needed.
Methods: A mixed-method study was conducted in Utah between October 2011 and December 2011. Eleven focus
group discussions were held and surveys were administered to 23 first-degree relatives of PCa patients living in Utah
and 24 primary-care physicians and urologists practicing in Utah to present specific information about these assessments
and determine knowledge and attitudes regarding health implications of using these assessments.
Results: Data was independently coded by two researchers (relative Kappa = .88; provider Kappa = .77) and analyzed
using a grounded theory approach. Results indicated differences in attitudes and behavioral intentions between patient
and provider. Despite the test’s limitations relatives indicated interest in genetic testing (52%) while most providers
indicated they would not recommend the test for their patients (79%). Relatives expected providers to interpret genetic
test results and use results to provide personalized healthcare recommendations while the majority of providers did not
think the information would be useful in patient care (92%) and indicated low-levels of genetic self-efficacy.
Conclusions: Although similarities exist, discordance between provider and patient attitudes may influence the effective
translation of novel genomic tests into clinical practice suggesting both patient and provider perceptions
and expectations be considered in development of clinical decision-support tools.
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Prostate cancer (PCa) is the most commonly occurring
non-cutaneous cancer and the second leading cause of
cancer deaths in American men [1]. In the U.S. in 2012,
approximately 241,000 new cases of PCa were diagnosed
and about 28,170 individuals died of the disease [2].* Correspondence: wendy.birmingham@byu.edu
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distribution, and reproduction in any mediumHaving one first-degree relative with PCa at any age is
associated with a twofold to threefold increased risk and
risk increases with the number of first-degree relatives
[3,4]. PCa risk is higher for men who have a brother with
the disease than for those with an affected father [5].
The American Cancer Society recommends men discuss
screening benefits and risks with their provider begin-
ning at age 45 for men with a first-degree relative diag-
nosed with PCa < 65 years and at age 40 for men with
two or more first-degree relative diagnosed with PCa <ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Force recently released their recommendation against
prostate-specific-antigen (PSA)-based screening for PCa
[6] claiming that additional research is needed to deter-
mine the benefits and harms of PSA in men with a family
history of the disease. These conflicting recommendations
may leave men with a family history of PCa uncertain
whether screening would be beneficial or harmful.
The strong association between family history and PCa
risk suggests a significant genetic contribution, yet un-
like breast and colorectal cancer in which highly pene-
trant predisposition genes have been found, specific PCa
susceptibility genes have yet to be identified. Certain sin-
gle nucleotide polymorphisms (SNPs) are correlated with
PCa risk [7-9]. Risk estimates for individual SNPs have
been associated with modest risk (OR ~ 1.1-1.8), but
when inherited in combination the risk may be more
pronounced [10]. Identification of these SNPs has led
to the development of genomic PCa risk assessments.
However, this testing is controversial as the functional
significance of these individual genetic variants is still
unknown and the clinical validity and utility of genomic
testing for PCa risk assessment is yet undetermined.
Such personalized approaches to PCa risk stratification
are largely unexplored and formative research on atti-
tudes, knowledge and interest in testing can help inform
future public health and clinical communications as well
as educational tools targeting both patients and providers.
Genomic testing for PCa susceptibility is available direct-
to-consumers (DTC) through internet web sites (i.e., 23
and Me) and provider-ordered through a CLIA laboratory
(ARUP). While this type of genomic testing is still contro-
versial [11,12], both the public and healthcare providers
are becoming more aware of its availability. Purchasing
genomic risk assessments online allows patients to bypass
their healthcare provider yet patients may have difficulty
interpreting test results and may request providers help in-
terpret results [13]. With increasing consumer interest in
genomic testing [14,15] and evidence that providers are
often not sufficiently educated in genetics to deliver clinical
genetic services [16-18] there is a need to develop optimal
strategies for appropriately educating patients and pro-
viders and to incorporate this information to inform health
care decision-making. Understanding both patients’ and
providers’ perspectives is crucial for effectively translating
genomic discoveries into practice and developing effective
decision support tools. Prior research has examined public
awareness and perceptions of general DTC testing as well
as provider knowledge and experience with general DTC
testing [16,17,19]. To our knowledge, there are no available
studies examining knowledge, attitudes, and interest in
PCa genetic DTC and clinical genetic testing in men at in-
creased familial risk for PCa and key providers who may
order or be asked to interpret results from such tests.The purpose of our study was to examine attitudes,
knowledge, and behavioral intentions regarding genomic
testing in relatives of men with PCa, and in providers.
Urologists and primary care physicians are the most
likely provider type to order genetic testing for PCa sus-
ceptibility or have patients ask them to interpret their
DTC test results [20-22]. Thus, we specifically targeted
these two subgroups. Our mixed-method approach in-
cluded focus group discussions with relatives and pro-
viders to gain an understanding of decision support needs
and inform the development of decision support toolsa.
We also administered quantitative surveys assessing can-
cer risk perceptions and genetic knowledge along with
questions specifically developed to assess knowledge, atti-
tudes about and interest in genomic testing.
Methods
Study design
Prior research indicates knowledge about and awareness
of SNP testing is still fairly low in the general popula-
tion. Therefore, to have a more informative discussion
we provided a minimal level of background information
through a brief education session that was conducted at
the beginning of each focus group session [23]. The
presentation for relatives included a description of well-
established risk factors including age, race and family
history, PCa screening guidelines, basic genetics (struc-
ture of DNA, explanation of SNPs), availability of SNP-
based testing for PCa, possible test outcomes (including
reviewing a sample report) and discussion of the benefits
and limitations of SNP testing. The presentation for pro-
viders included information on SNP testing and valid-
ation of studies. While the study focuses on interest in a
genomic test, the testing was described as genetic rather
than genomic during the presentation as participants
were more likely familiar with that terminology.
Additionally, SNPs occur at different frequencies in
different racial populations. Therefore studies evaluating
the role of SNPs in one population cannot necessarily be
extrapolated to other racial groups. At the time of this
study certain PCa tests were based on European popula-
tions. Because availability and accuracy of testing varies
between racial and ethnic groups, it is important to seek
out representation from diverse populations. Thus we
stratified focus groups by race/ethnicity.
The use of focus groups is a well-validated method-
ology [24,25] and is particularly appropriate for examin-
ing translational issues regarding emergent technologies
that are not yet routinely used in clinical practice [25].
Pre-focus group surveys for relatives assessed knowledge
about and attitudes toward genetic testing, current PCa
screening practices, knowledge of general genetics and
genetic testing and standard demographic information.
Pre-focus group surveys for providers assessed current
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sults of genetic testing, genetic self-efficacy and demo-
graphic information. Post-focus group surveys assessed
attitudes toward the information presented during the
focus group as well as providers’ likelihood of using gen-
omic testing in clinical decision-making. The research
protocol was reviewed and approved by the Internal Re-
view Board of the University of Utah.Table 1 Relative and health care provider focus group
composition







Non-Latino White 4 3-5 17
African American 1 3 3
Latino 1 3 3
Providers
Urologists 1 9 9Participants and setting
The relative subgroup consisted of 23 men aged 45–70
with at least one first-degree relative with PCa. Seven-
teen men had an affected father and 6 had an affected
brother. Participants were recruited from the community
through newspaper advertisements (n=7), local organiza-
tions (n=3), clinics at Huntsman Cancer Hospital (HCH)
(n=8) and through the Utah site of the National Cancer
Institute Cancer Genetics Network (CGN) (n=5) -a US
national registry of individuals with a personal or family
history of cancer [26]. Physicians from HCH clinics
identified and gave permission to approach PCa patients.
Study staff provided information about the study and re-
quested permission to contact patients’ male unaffected
first-degree relatives. Relatives were then sent a letter
explaining the study, a consent letter and asked for per-
mission to contact. CGN staff contacted unaffected rela-
tive enrollees to request permission for study staff to
contact them about the study. Once permission to con-
tact was obtained, staff screened the potential participant
for eligibility over the phone, obtained consent participa-
tion and assigned participants to a focus group based on
race/ethnicity. Relatives recruited through advertisements
placed in a local newspaper and through community orga-
nizations were also screened for eligibility, consented and
assigned to a focus group by phone.
Twenty-four providers were recruited through Hunts-
man Cancer Institute (n=6), community urology prac-
tices (n=8), and community practice clinics (n=10). Of
these, 10 were primary care physicians and 14 were urol-
ogists or urology residents. Inclusion criteria for relative
and provider groups included no personal history of
cancer except non-melanoma skin cancers, no prior can-
cer risk counseling or evaluation and English fluency. All
relative and provider participants who were screened
eligible and assigned to a focus group completed the
baseline survey, attended their assigned focus group and
completed the post survey. Information on the compos-





Baseline and post focus group measures are presented in
Additional file 1.Procedures
Relative focus groups were stratified by race/ethnicity.
We held 4, 1 and 1 focus groups with non-Latino Whites,
African-Americans, and Latinos, respectively. Provider
focus groups were stratified by practice specialty with two
urology focus groups and three primary-care focus groups.
All focus groups were facilitated by the same moderator
(WCB) and the educational presentation was given by a li-
censed genetic counselor (WK). Relative group discussions
lasted approximately 120 minutes and provider group dis-
cussions lasted 90–120 minutes. All participants received
compensation ($50 for relatives) or an honorarium ($150
or an Amazon Kindle e-reader for providers).
Pre-focus group surveys were mailed to participants
and they returned the completed surveys at their assigned
focus group meeting. Each focus group session began with
the educational presentation. Information was presented
on genetic testing and participants were shown a sample
report from deCODE genetics, an online company that of-
fered DTC testing at the time of this studyb. The provider
educational presentation included information on statis-
tical calculations used to obtain risk estimates by online
companies offering testing, and potential benefits and lim-
itations of testing. Educational information presented to
focus group participants is outlined in Additional file 2.
Participants were then led in discussion by the moderator
using a semi-structured moderator guide consisting of a
series of open-ended questions. Immediately following the
discussion participants completed post-focus group sur-
veys. Focus groups were audio-recorded and transcribed
verbatim by a professional transcription service and veri-
fied for accuracy by a research team member (MW).
Data analysis
Descriptive analyses of questionnaire items were conducted
using SAS 9.2 (SAS Institute Inc., Carry, NC, 2002–2010).
Frequencies, percentages and measures of central tendency
Table 2 Characteristics of study participants
Relatives
Age, mean (standard deviation) 57 years (6.3)
n %
Ethnicity/Race
Non-Latino White 17 74%
African American 3 13%
Latino 3 13%
Employment
For wages 18 78%
Self-employed 1 4%
Retired 4 18%




$70,000 or more 13 56%
Education level
High school or GED 2 9%
Some college/AA, AS 9 39%
College graduate 7 30%
Postgraduate degree 5 22%
Healthcare providers
Age, mean (standard deviation) 46 years (12.9)
n %
Specialty
Primary care 8 34%




Primary practice 10 42%
Community urology 8 33%
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Ltd. Version 9, 2010) was used to code of focus group
transcripts. All focus group transcripts were reviewed by re-
search team members and a grounded theory approach
[16,27,28] was used allowing codes, concepts and categories
to emerge from the data. Our approach consisted of open
coding of the data, organizing the data into segments based
on key words and concepts to form categories and identify
patterns and major themes in the focus group narratives.
Interpretation of the data was discussed among the re-
search team and all transcripts were then independently
coded by MW and WCB line by line. Inter-rater reliability
was determined by calculating Kappa statistics (relative
transcripts = .88; provider transcripts = .77) and with over-
all percent agreement (98%).
Results
Overall, no differences were found between the racial
groups in their interest in and motivations for testing, thus
groups were collapsed for analysis. Demographic informa-
tion of relative and providers is presented in Table 2.
Survey results
Relatives
Baseline survey data indicated most relatives had not
heard about DTC genetic testing (61%). Most relatives
(67%) believed their own risk of PCa was great or very
great and approximately half (56%) were somewhat or
moderately worried about getting PCa. Fifty percent of
relatives believed that genes determine how a person’s
health behavior impacts his or her health. Relatives were
divided with 35% agreeing or strongly agreeing, 43%
disagreeing and 22% neither agreed nor disagreed that
genes were more important than one’s own behavior in
determining health. However, most (92%) believed that
healthy behaviors could reduce the risk of disease for
people who have a gene for a particular disease. Regard-
ing PCa screening behavior, most relatives in our study
had previously had a digital rectal exam (78%), 53% within
the prior year. In addition, most had previously had their
PSA levels tested (74%) with 63% reporting a PSA test
within the prior year. Furthermore, nearly one-third of rel-
atives had initiated conversations with their provider re-
garding cancer screenings (29%) because their provider
had not brought it up, and more than half (55%) of rela-
tives indicated their providers had not talked with them
regarding their familial PCa risk.
Post-focus group survey data indicated most relatives
(52%) were interested in obtaining the PCa SNP test
and most (56%) would prefer to order it through their
provider rather than on their own. Most relatives (96%)
found the focus group presentation was helpful and free
text comments indicated it was easy to understand and
informational.“…all of it was informational and easy to understand.”“All was straight forward.”
Three relatives felt the lifetime risk estimates were dif-
ficult to understand and two relatives felt the presenta-
tion was biased toward getting the genomic testing; all
other relatives indicated they liked the presentation and
did not find the information too difficult to understand.
Table 3 Themes identified from focus group discussions
Themes Definition % inter-rater
agreement
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Baseline survey data indicated that half of the providers
had not heard or read about PCa DTC genetic testing.
Most providers (92%) had not had a patient ask ques-
tions about DTC testing nor present results for inter-
pretation. Although 42% of providers said they felt
confident in their ability to assess risk of hereditary dis-
orders, 92% did not feel confident discussing the bene-
fits, risks and limitation of genetic testing with patients
indicating low levels of provider genetic efficacy. Add-
itionally, providers did not feel confident answering pa-
tients’ questions about DTC genomic tests (96%), did
not feel prepared to answer patients’ questions about
DTC genomic testing (79%) and did not feel confident
in their knowledge of cancer genetics (74%). Providers
were also concerned that increased-risk results could
unnecessarily increase patient anxiety (74%). However,
most agreed test results could help inform the age at
which to start (86%) and frequency of recommended
screenings (76%).
Post-focus groups surveys indicated most providers
(92%) did not think SNP PCa test results would be
useful in the management of patients, and most (79%)
indicated they would not recommend SNP testing for
PCa for their patients. Free text comments indicated
providers believed SNP testing had too many limitations
and was not practical or clinically useful.
“…Not sure if current tests are ready for prime time.”
“…not validated by prospective studies.” “…not






Benefits/ risks of Relatives’ perceived benefits and 99%“data is not compelling enough and seems more likely
to lead to dilemma in interpretation and further




Relatives’ trust in provider and
belief provider will use testing





Relatives’ intention to change
diet, exercise and screening






Providers’ belief in own ability to










Providers’ beliefs concerning test
validity and intentions to use





Providers’ belief patients will alter
behavior
98%“It does not add any new information that PSA,
history and digital rectal exam offers”
Free text comments also indicated that while overall
the providers found the presentation clear and inform-
ative they wanted more detailed information on SNP
testing validity.
Focus group findings
Several themes emerged from the focus group discus-
sions. The main themes are outlined in Table 3.
Relative focus group discussions
Knowledge of genetics Many relatives had not heard
about PCa genomic testing and generally believed genetics
were more important in determining PCa risk than behav-
ior or environment. Many indicated a deterministic atti-
tude. Relatives cited the value of PCa screening for earlydetection of disease but, when speaking of SNP testing,
they often interchanged information obtained from screen-
ings (i.e., detection of disease) with information obtained
from genetic testing (i.e., risk of disease at a future date).
“Almost 70% of men get it anyway, and we’re double
that, at least, if not triple that. So I might be negative
or whatever, but I’ve come to the conclusion that I’m
probably going to get it no matter what.”“In my family it’s almost a given because there are
so many people with it. It’s like, yeah, it’s part of
life.”
Benefits and risks of testing Relatives articulated a
range of opinions regarding the benefits and risks of
genomic testing. Most indicated knowing their risk would
not give them additional information beyond their family
history. Several indicated their belief that diet or exercise
modifications would not reduce PCa risk; therefore know-
ing genetic susceptibility would not be useful. But other
relatives noted they would be interested in knowing their
own genetic risk and results might help them make more
informed healthcare decisions (i.e. screenings). Relatives
also expressed an interest in testing simply to satisfy their
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any healthcare decisions.
“It would be interesting just to know where I fell in the
risk factor, having a family history of it. It would be
interesting to know if I fall above, or below, or right in.
It would just be interesting to know.”
Relatives also voiced concern that a lower-risk test
result might give a false sense of security and lead to de-
creased utilization of PCa screening. Several relatives
believed testing would be more beneficial to younger in-
dividuals (i.e., their sons) as younger men could then
make decisions regarding earlier screening behavior. Dis-
cussions also focused on the anxiety that could be cre-
ated by an increased-risk result.
“But it seems like this would be better for somebody in
their twenties or thirties rather than a bunch of old
guys who already know they’ve had somebody die in
their family of a certain disease and can kind of look
at what has happened to their ancestors.”“If you already know that, because of your family
history, you have an elevated risk of getting prostate
cancer, what more is this going to tell you other than
what you already know?”“I would think this test would be more accurate
because I really don’t know what my family history is.
My father’s the only one that lived long enough, so I
don’t know what my family history is.”“Sometimes being ignorant and blind is better than
going out there and worrying yourself to death because
I have 2.5 times the risk of somebody else getting it.”“Or if it comes back real low and gives you a false
sense of security. ‘Hey, I don’t need that [to get
screened]. I don’t have any problems.”
Provider trust and personalized healthcare Most rela-
tives in our study indicated they had not discussed PCa
genomic testing or DTC testing with their provider.
However, despite this lack of discussion, overall, relatives
indicated they trusted providers to recommend genetic
risk testing and to interpret the test, preferring their
own provider over genetic counselors.
“Well, I’d ask him first since he’s the one I see all the time.
Then if he can’t do it, he can refer me to somebody else.”“I would [go to my internist] just … because that’s kind
of where you get the information from now.”Further, relatives indicated they expected their pro-
viders to interpret and use results to provide personal-
ized healthcare recommendations.
“I’d want my doctor to explain it to me so I
understand it fully. That would be the information
I’d want.”“And I would expect my doctor to personalize my care,
directed at these higher numbers, in terms of what he’s
looking for.”“This is what it has come up with for me personally.
I’d expect them to make some recommendations.”“I would like him to give me some advice on
how best I can avoid getting prostate cancer based
on this.”“This says that I was at a 35% increased risk and my
lifetime risk was 22%… I would expect the doctor to be
more aggressive in annual exams.”“What my physician could do with this is, he
would overlay my history and my relatives’ histories
and use it as one of the factors that he would say
‘we ought to do an exam every nine months instead
of every year,’ or something like that. Maybe he
would increase or decrease the length between
exams.”
Most relatives indicated they preferred to order the
test through their provider, rather than DTC. Some were
unsure whether they would go to their regular provider
or to a specialist (i.e., genetic counselor) but most agreed
they would consult their own provider first and follow
his/her recommendations.
“I’d rather have my doctor order it because he knows
exactly what to order. I wouldn’t know all the ins and
outs of it.”
Behavioral intentions Discussion about behavior modi-
fication following test results indicated relatives would
use test results to change behaviors such as diet and
exercise and would be more diligent in screening
practices.
“I think it would motivate me to get tested more
often, because I know I have a family history now
and I don’t [get screening tests]. I get tested once
every year or every two years. I would probably
request to be tested more often to try to catch it
earlier.”
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like that as well, but as far as the screening process
goes, I’d do everything possible there is.”
As the discussion progressed, however conversations
centered on behavior recommendations made in the past
by providers because of other co-morbidities such as dia-
betes and cardiovascular disease. Relatives acknowledged
they had not followed their provider’s lifestyle recommen-
dations (i.e. lose weight, exercise more, eat a diet lower in
saturated fats) and would probably not follow lifestyle be-
havior modification recommendations made by their pro-
vider in relation to PCa susceptibility testing.
“If it was higher, I’d go for testing, but I probably
wouldn’t change how I eat because I have other
reasons I should change how I eat and I didn’t. I’m
miserable being fat, but it’s like a dog lying on the
porch on the nail. It must not hurt it enough.”“So have either one of us actually followed that
advice? I know I haven’t.”“I wish it were true that when I received information
that I would act on it in the way I ought to, but I don’t
always. I mean, you get back your cholesterol results or
whatever and they aren’t in nearly such a wonderful
graphical form, but you still know, ‘Oh, I need to cut
down on steaks,’ or whatever. But have I? I have a
father who’s died of prostate cancer, but I’m still 30 to
40 pounds overweight. So is this going to change my
behavior? I wish I could say it would, but I don’t know
that it’s going to.”
In addition, relatives expressed uncertainty regard-
ing whether diet or exercise would reduce their PCa
risk:
“There isn’t anything dietary you can do to prevent
prostate cancer. I’ve heard that a diet high in
tomatoes might help. I don’t know where I read that,
but I did read it.”“Fat men are no more likely to die of prostate cancer
than skinny men or tall men or short men or what?
You don’t know”.“I didn’t think behavioral or environmental really had
much of an effect on prostate cancer.”
Relatives indicated, however, that they would likely
follow physician recommendations regarding PCa cancer
screenings, increasing frequency or screening earlier
than would otherwise be indicated by age or familyhistory. Most relatives had favorable attitudes toward
PCa testing and indicated interest in being tested.
Providers
Self-efficacy in cancer genetics Consistent with our
survey findings, focus group findings indicated providers
were not confidant interpreting genetic results or ex-
plaining results to patients.
“And sometimes I have to sit and think about ..[the
results] because like you said, just in that little
discussion we had, we were all looking at it [statistical
computation of risk]and going, now wait a minute,
what is this and what is this?”“…I hated statistics, now you are asking me to give
relative risk versus lifetime risk.”“Yeah, except when you try to explain that [the
results], just think of the hard time we had just trying
to get it square in our minds what all these SNPs
were. Try explaining that to a patient.”
Providers also indicated they would prefer to refer pa-
tients to genetic counselors for genetic testing.
“I think I would prefer to order it though a genetic
person that could help interpret, because again, then
you get back to the testing, and what do you do with
it?”
Concerns regarding patient wellbeing
Similar to attitudes expressed by relatives, providers also
expressed concerns that decreased-risk results would
create a false sense of security and thus patients may not
adhere to screening recommendations.
“What worries me is a patient that would have that
kind of a family history and go pay for a genetics
profile that says that they’re safe, so they decide not to
go see their physician and not talk to somebody about
it and put their head in the sand. That’s the patient I
worry about more than somebody who comes in to
talk to me.”
Most providers expressed concern that increased-risk
results could increase patient anxiety and would lead to
unnecessary testing and unnecessary costs to both pa-
tient and the healthcare system.
“I would wonder looking at that whole thing how
many blood tests, ultrasounds, and things I’d end up
doing and in this day and age of cost containment,
wow. Because again, all you’re looking at are
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to order all those tests to rule it out.”“…it’s like why are we doing a test that raises anxiety
and increases the cost of care?”
Providers also expressed concern that test results
could put patients at risk for discrimination by insurance
companies and employers.
Test validity/clinical utility
Providers expressed concern regarding the validity of the
PCa genomic test and overall clinical utility. Most pro-
viders would not recommend genomic PCa susceptibility
testing for their patients, and did not think it would be
useful in the management of patients. In general, pro-
viders strongly believed that family history was a better
indicator of possible future disease.
“The problem with this is … how does that change
what we already know from years and years of PSA,
age, family history, all the normal clinical things…?”
Providers also indicated that they did not have suffi-
cient time to counsel patients regarding the benefits and
risks of genomic testing or interpret test results.
“To take the time to understand this report, which is
not something that I’m going to have seen on a regular
basis, is going to take more time than I have and I
would be quite annoyed if a patient brought this in.”“It’s a great segue into a big discussion about prostate
cancer, but that’s a discussion that’s not a 10-minute
discussion; it’s an hour discussion. … in real practice
that’s not an easy thing to do.”
However, although providers indicated that they likely
would not order the test for their patients, if a patient
brought the test results to them for interpretation they
would likely recommend enhanced screening practices (i.e.
earlier age and/or more often than guidelines recommend)
regardless of whether test results showed increased or de-
creased risk. Discussions focused on concerns about pa-
tient anxiety and several providers indicated that if a
patient were sufficiently motivated to order the test DTC,
the provider would be medically and legally obligated to
recommend screening earlier or more frequently than
guidelines recommend.
“Then we would probably order it [more tests] because
medical/legally, if they asked for it and we didn’t order
it and they happened to be the odd one that would
have picked something up, I’m cooked.”“But if they brought their test to me and they had
done it because they were worried; I couldn’t just
discount it. I couldn’t.”“…. I would feel compelled to do something extra for
the patient, probably screen more frequently.”“I wouldn’t counsel somebody based on the results ….
[but] I would be more vigilant about screening them if
they were at higher risk.”“…. and the only thing I would say is for the person
who wants this test, I would start screening them
earlier.”
Belief in patient behavioral change
Providers indicated their belief that increased-risk test
results might motivate patients to adhere to screening
recommendations. They also suggested that patients
who are sufficiently motivated to obtain testing would
also likely be highly motivated to adhere to screening
recommendations.
“If you could have this test that shows a significantly
higher risk of developing prostate cancer, it could be
the impetus to get proper screening. If you have the
reluctant patient, perhaps this test would be helpful.”“It might actually, if a patient sees the increased risk,
increase their compliance as far as coming in for
regular exams or at least being willing to get the
digital rectal exam.”“I think for people who are doing it now, because
they’re willing to fork over [the money] to get some
information, those are the type of people I think are
motivated to do something about it.”
However, providers indicated they did not believe pa-
tients would alter lifestyle behaviors (e.g., diet and exer-
cise) based on genomic results.
“You can’t get people to do some of these things
[adhere to diet and exercise recommendations] that we
have known for years and have good statistical
information. We can prove it over and over again how
much more beneficial it would be for them and we
can’t get them to do it. You get a test like this, and I
don’t know if it would help or not.”“You talk to your patient about ‘if you would lose
weight your incontinence would be better, your knee
arthritis would be better’; this would be better, that
would be better. You wouldn’t have diabetes anymore.
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You wouldn’t have to wear a CPAP. You do all those
things and people still stay the same.”
Discussion
The translation of genomic discoveries into public health
practice has been slow [29-32]. At a time when the bene-
fits of PCa screening are uncertain it is essential to under-
stand the value of genomic information in motivating
healthy behaviors and medical decision-making in persons
at increased risk of the disease and providers. Since the
collection of our data the U.S. Preventive Services Task
Force (USPSTF) released their recommendation against
PSA-based screening for PCa [6]. The American Cancer
Society [5] continues to recommend men make an in-
formed decision with their provider about whether to be
screened for PCa [5]. The inconsistency regarding PCa
screening makes medical decision-making in this context
even more challenging for both consumers and providers.
Understanding how both consumers and providers regard
PCa susceptibility testing can help determine how to best
formulate decision support tools and interventions to
guide appropriate healthcare decisions. Yet, while prior
studies have examined consumers’ [33-35] and providers’
[16,18,36] knowledge and attitudes regarding general DTC
genetic testing, our study is among the first to specifically
examine both at-risk men’s and providers’ attitudes and
knowledge regarding PCa susceptibility testing. Thus, our
study’s findings provide a unique contribution to the lit-
erature regarding the knowledge, attitudes and behavioral
intentions in both men at familial risk of PCa and in pro-
viders most likely to order or interpret genetic testing for
PCa susceptibility.
Prior studies have reported low levels of awareness of
DTC testing [37-39]. Our findings support these studies,
documenting low levels of awareness about genetic testing
in general and PCa susceptibility testing in particular.
Similar to relatives, and also supporting prior research
[16], primary care providers in our study had low levels of
awareness of DTC genomic testing. Moreover, urologists
in our study exhibited low levels of awareness with only
half indicating they had heard or read about DTC genomic
tests. It is noteworthy that relatives in our study and par-
ticipants in prior studies [22] have indicated that they pre-
fer to obtain and discuss genetic testing through their own
provider, yet both primary care physicians and urologists,
the two providers most likely to provide medical advice to
men at increased PCa familial risk exhibit low levels of
awareness about this type of genomic testing. This limited
awareness as well as low levels of genomic efficacy could
impact patient-provider communication about PCa sus-
ceptibility testing.
We observed appreciable differences in relatives’ and
providers’ attitudes toward PCa genomic testing. Providersidentified limitations of the genomic risk panel and
expressed concerns about the test’s clinical validity and
utility. The majority indicated they would not order the
test for their patients and would not use PCa genomic
testing to guide healthcare decisions, preferring to use
family history when making screening recommendations
for their patients. However, while relatives may not have
found testing to be helpful in making lifestyle choices (i.e.,
diet, exercise), most relatives in our study indicated inter-
est in testing, both to understand genomic factors that
may help with screening decision-making and also simply
out of curiosity. In fact, many relatives in our study indi-
cated they would get the test simply because it would be
interesting. These findings also support prior research on
public interest in genomic testing interest [35]. Despite
citing curiosity as a reason for testing, relatives expected
their provider to interpret the results and make healthcare
recommendations based on their test results. Relatives in
our study also indicated that they trusted their providers
could and would accurately interpret the test results, and
most would seek out their own provider for information
to help them make an informed decision about testing, ra-
ther than seeing a genetic specialist. However, primary
care physicians and general practitioners have consistently
reported low genomic self-efficacy [16,18]. Providers in
our study similarly indicated low confidence in discussing
benefits and risks of genetic risk testing with patients. Fur-
thermore, many providers in our study indicated they did
not have time to counsel patients about genetic issues,
and would prefer to send patients to a genetic counselor
for testing and have them interpret the test results. Pro-
viders were concerned that decreased-risk results would
lead to less compliance with screening recommendations.
They also believed that increased-risk results would lead
to greater anxiety and unnecessary procedures which in
turn could lead to unnecessary costs to the patient and to
the healthcare system. Additionally, most providers in our
study had not encountered patients’ questions regarding
DTC testing. Similar findings are reported in the litera-
ture, [16] suggesting that providers may lack confidence
because they lack experience. This lack of experience and
self-efficacy could influence providers’ ability to help pa-
tients make informed decisions about testing and how to
cope with the test results.
While relatives’ expectations of providers in our study
are consistent with patient expectations in prior research
[35], many relatives also indicated that although they
would consider enhanced screening, they did not think
genomic information added value to family history infor-
mation. This contradicts other studies examining public
attitudes toward genomic testing [39]. One possible ex-
planation for this attitude may be the relatives’ belief that
neither diet nor exercise could reduce their PCa risk
despite scientific evidence suggesting some associations
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[40-44]. If individuals believe there are steps they can take
to eliminate or reduce a risk, then information about that
risk can be advantageous. For instance, if individuals re-
ceive genetic cancer risk information related to increased
risk for skin melanoma and they believe they can take
steps to reduce the risk through behavior change (i.e. limit
sun exposure; wear sunscreen), then genetic risk informa-
tion may demonstrate clinical utility [45]. However, while
relatives indicated their belief that healthy behaviors could
reduce the risk of disease for people who have a gene for a
particular disease they also indicated they did not be-
lieve lifestyle changes would reduce their own PCA risk.
Thus they may have felt that genetic information would
not help them make lifestyle behavior changes that
would be beneficial.
We observed similarities in providers and relatives atti-
tudes toward lifestyle behavior change. Relatives indicated
they would follow enhanced screening recommendations
based on risk results but admitted they might not follow
through if their provider made lifestyle recommendations
for diet and exercise behavior changes. Providers indicated
they would recommend enhanced screening for patients
who had received genetic risk testing and also believed rel-
atives would likely not make diet and exercise changes.
Noteworthy is the finding that while providers believed
family history was sufficient for making screening recom-
mendations, most relatives had not had a conversation
with their own provider about their PCa family history.
Further, nearly one-third of relatives indicated they had
initiated conversations with providers regarding PCa
screening because the provider had not initiated the con-
versation. This is informative, as the new USPSTF guide-
lines recommend against PSA testing but recognize the
common use of PSA screening in practice today. The
guidelines suggest that patients requesting PSA screening
be provided with opportunities to make informed choices;
thus providers should be prepared to discuss screening
benefits and risks. Our study appears to support the no-
tion that while providers may not recommend PSA testing
they may be asked to provide screening tests as most rela-
tives in our study had their PSA levels tested within the
prior year despite the lack of patient/provider communi-
cation about this issue.
Another important finding in our study concerns over-
utilization of health services. As discussed, providers have
low levels of confidence in providing genetic services and
indicated they would not order testing for their patients.
Yet if patients presented them with their test results, pro-
viders indicated they would recommend enhanced PCa
screening regardless of test result outcomes. Providers stated
that if a patient was sufficiently concerned to order a test,
then the physician would increase screening recommenda-
tions. There is considerable controversy surrounding PCascreening including over-diagnosis and over-treatment of
clinically indolent cancers that can result in treatment-
related side effects and incur unnecessary healthcare costs
and burdens on the healthcare system [46]. Concerns have
been raised that consumer use of genomic testing may lead
to over utilization of health care systems. Our results indi-
cate this may occur not because physicians believe the test
results indicate the need for more diligence in patient sur-
veillance, but because physicians worry about medical and
legal responsibility if they do not adequately address test
results with increased screening. Our findings underscore
the need for educating both consumers and providers re-
garding genetic testing based on an understanding of both
perspectives. Decision-support tools are vital to both pa-
tients and providers to ensure that patients are made aware
of the risks and limitations of genetic testing and providers
make healthcare decisions for their patients based on their
patients’ clinical characteristics.
It should be noted that this was a pilot study and as
such our sample was fairly small and homogenous: rela-
tives were primarily non-Latino white and well educated
with higher incomes. In addition, we drew our sample
from one geographical area and relatives’ attitudes and
knowledge might not be generalizable to other geo-
graphical areas, or to lower education or income levels.
Provider’s genetic awareness and knowledge might also
differ by geographical location. It is also worth noting
that the relatives in our study consisted of men who
were aware of their increased risk for PCa via their own
family history. It could be that their awareness of this
risk influenced their interest in testing. Future research
should concurrently examine testing interest in men
with and without family histories of PCa.
Additionally, the education session was created to pro-
vide a minimal level of information and was presented
without bias toward or against SNP testing. We did not
measure genomic knowledge levels in the post-focus
group surveys, thus we could not determine whether the
education session had changed genetic understanding and
thus testing intentions. It would be of value for future re-
search to include measures that assess changes in genetic
understanding following focus group discussions.
Conclusion
Our study provides novel information about the atti-
tudes and intentions of individuals at high-risk for PCa,
as well as providers who may order, interpret or use re-
sults from PCa susceptibility tests in clinical decision
making for these particular individuals. Our findings also
demonstrate the value of examining both patient and
provider attitudes, knowledge and behavioral intentions.
An understanding of both patient and provider similar-
ities and differences may influence the effective transla-
tion of novel genomic tests into clinical practice. Our
Birmingham et al. BMC Health Services Research 2013, 13:279 Page 11 of 12
http://www.biomedcentral.com/1472-6963/13/279results are consistent with previous studies about DTC
testing in the general public, and further serve to docu-
ment the need for decision-support tools for both con-
sumers of genomic testing and health care providers.
Endnotes
aParticipants were not offered DTC testing as part of
this study.
bdeCODE Genetics is no longer offering DTC genetic
testing.
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